Table 1 c-Myc-deficient B cells are resistant to treatment with anti-CD95 antibody or staurosporine

From: Erratum: c-Myc-deficient B lymphocytes are resistant to spontaneous and induced cell death

Sub G0/G1 (%)

αCD40

αCD40+IL-4

—

αCD95

+Staur

—

+αCD95

+Staur

Exp 1

      

c-myc +/▵

15%

70%

ND

7.0%

35%

ND

c-myc ▵/▵

18%

43%

ND

7.1%

14%

ND

Exp 2

      

c-myc +/▵

8.8%

70.8%

ND

6.5%

35.4%

ND

c-myc ▵/▵

8.6%

22.8%

ND

4.7%

17.5%

ND

Exp 3

      

c-myc +/▵

11.6%

66.9%

ND

5.5%

28.8%

ND

c-myc ▵/▵

5.8%

41.1%

ND

5.5%

14.2%

ND

Exp 4

      

c-myc +/▵

13.7%

68.1%

33.1%

9.1%

35.9%

26.1%

c-myc ▵/▵

5.4%

44.2%

7.1%

3.7%

15.6%

7.7%

Exp 5

      

c-myc +/▵

12.3%

54.7%

33.6%

11%

35.3%

30.4%

c-myc ▵/▵

3.4%

30.8%

11.1%

1.2%

7.9%

3.5%

Exp 6

      

c-myc +/▵

9.4%

 

38.8%

9.8%

 

25.5%

c-myc ▵/▵

6.6%

 

9.5%

7.0%

 

7.1%

  1. Same numbers of sorted B lymphocytes were activated with either anti-CD40 antibody (10 μg/ml) or anti-CD40 plus interleukin 4 (20 ng/ml). At 48 h after stimulation, cells were either treated with anti-CD95 antibody (+αCD95, 100 ng/ml, Jo2 Pharmigen) or staurosporine (+Staur, Sigma, 20 nM), or nontreated (−). The table shows percentages of cell death (sub-G0/G1 values) by propidium iodide staining of six independent experiments. ND, not done
Back to article page